Cargando…
Hyaluronate supports hESC‐cardiomyocyte cell therapy for cardiac regeneration after acute myocardial infarction
INTRODUCTION: Enormous progress has been made in cardiac regeneration using human embryonic stem cell‐derived cardiomyocyte (hESC‐CM) grafts in pre‐clinical trials. However, the rate of cell survival has remained very low due to anoikis after transplantation into the heart as single cells. Numerous...
Autores principales: | Tan, Yuanqing, Wang, Lei, Chen, Gang, Liu, Wenjing, Li, Zhongwen, Wang, Yukai, Wang, Liu, Li, Wei, Wu, Jun, Hao, Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705924/ https://www.ncbi.nlm.nih.gov/pubmed/33107673 http://dx.doi.org/10.1111/cpr.12942 |
Ejemplares similares
-
c-JUN is a barrier in hESC to cardiomyocyte transition
por: Zhong, Hui, et al.
Publicado: (2023) -
Phase 1 trial for treatment of COVID‐19 patients with pulmonary fibrosis using hESC‐IMRCs
por: Wu, Jun, et al.
Publicado: (2020) -
First case of COVID‐19 infused with hESC derived immunity‐ and matrix‐regulatory cells
por: Wu, Jun, et al.
Publicado: (2020) -
hESCs‐Derived Early Vascular Cell Spheroids for Cardiac Tissue Vascular Engineering and Myocardial Infarction Treatment
por: Liu, Yang, et al.
Publicado: (2022) -
Treatment with hESC-Derived Myocardial Precursors Improves Cardiac Function after a Myocardial Infarction
por: Ye, Jianqin, et al.
Publicado: (2015)